Tag is: Sale of goods

Inditex, owner of Zara’, challenges ’'s war concerns with strong sales in Iran

by the Logistics TransportIn the the General Assembly

Inditex, the Spanish fashion giant behind Zara’, announced its annual launch in the first quarter. %It posted a net revenue of €1.4 billion, up 5.4 percent, and exceeded market expectations.

the Sales Department %8.7 billion Euro’ya with an increase of 5.8, i.e. at constant exchange rates %8.8’e increased; Analysts are roughly %It's beyond the 8’ estimation.

Gross profit, with the help of improvement in profit margins %EUR 5.4 billion increased to ’ with an increase of 6.9; This means that the company retains a larger share of revenue as profit. EBITDA, a measure of basic earnings %An increase of 7.3 to 2.6 billion Euro’.

Inditex shares on Wednesday after the company reported a strong start to the second quarter. %It has risen to more than 5’; Sales from May 1 to June 1 %It increased by 11.5, which assured investors that the Zara owner remained resilient despite signs of weakening consumer spending.

Mamta Valechha, discretionary consumer analyst at Quilter Cheviot’, said “Inditex maintained its strong momentum with recent results that exceeded first-quarter expectations and made a strong start to the second quarter as sales rose more or less in line with the company's previous quarter.

The increase in revenue from one of the world's largest clothing retailers points to strong consumer appetite towards the summer, despite concerns that the more uncertain economic and geopolitical environment could put pressure on spending in the coming months.

Managing geopolitical risks

The results come at a time when businesses around the world are facing growing uncertainty about the global economy and concerns that consumers could cut spending.

Inditex said its wide-ranging supply chain and flexible transportation network have helped keep products flowing to stores worldwide despite recent outages.

Quilter Cheviot’'s discretionary consumer analyst Mamta Valechha, “, said that ultimately Inditex continues to have a flexible business model that can withstand significant economic pressures and currency fluctuations.

He said strong customer demand and the company's ability to supply products close to its main markets helped him keep collections up to date while limiting the need for discounts. Efficiency improvements have also helped maintain profitability.

Retailer, geopolitical tensions, Barclays’in revenue approx. %He acknowledged that he had influenced sales in the Middle East ’, which he estimated formed 5’ini.

Inditex also notes that the current “geopolitical challenges of ”, Barclays’in's revenue is approx. %He also said it had an impact on sales in the Middle East ’, which he estimates constitutes 5’ini.

The company also warned that ongoing instability in the region could affect its performance in the coming months.

Inditex faces a number of other challenges, including higher shipping costs and rising prices of raw materials such as cotton and polyester. Currency movements are also expected to weigh on the results this year.

Inditex completed the quarter with 5,456 stores and a net cash position of €10.8 billion.

For the last fiscal year, in May and November 2026, the Board proposed a dividend of 1.75 euros per share, consisting of the usual component of 1.20 euros and a bonus of 0.55 euros to be paid in two installments in ’.

Although Inditex made a strong start to the year ​​, it did not change its appearance. He said he expects sales growth to continue in the second quarter, supported by strong demand for spring and summer collections and ongoing improvements to its stores and operations.

However, the company believes that currency fluctuations are likely to increase sales all year round. %He said he'd cut it down by about one. It also expects to invest around 2.3 billion euros in the business in the current fiscal year.

Bayer’in shares on the rise as company registers strong cancer drug demand

by the Logistics TransportIn the the General Assembly

German pharmaceutical giant Bayer’in shares were listed on the London Stock Exchange on Tuesday morning after the company increased demand for new cancer and kidney drugs in the first quarter of 2025. %It's up 10 and a half.

Interest, tax, depreciation and pre-depreciation earnings (EBITDA) before special items amounted to €4.1 billion in the first quarter of 2025. This is compared to the same quarter of the previous year. spite a 7.4-decrease, it was still above market expectations of €3.9 billion, according to Bloomberg’.

Group sales in the first quarter compared to the same quarter of 2024 %-0.1 billion euros, down 13.7 billion euros. If the core gain per share is %It declined 11.7 to 2.5 Euro’.

Bayer’'s CEO, Bill Anderson, was optimistic that the increase in earnings in the pharmaceutical division was a sign that teams were learning to do more with less. He also reiterated his confidence in the company's fundamentals and the momentum of its launches.

The company also said it is closely monitoring ongoing economic and geopolitical changes, as well as their impact on the company.

Bayer has confirmed its outlook for 2025 at constant rates and expects the pharmaceutical division to perform at the top of its previously shared sales and profitability expectation range.

Bayer’in pharmaceutical division grows as plant science slows

Although sales of the Bayer’in pharmaceutical division lagged behind the European, Middle East and African (EMEA) region, they were mainly driven by North American sales in the first quarter of 2025. %It's up 4.4.

The company's new hormone therapy drug for prostate cancer, Nubeqa, has seen significant demand along with Kerendia, which is used to treat chronic kidney disease.

While sales of Eylea’, which is mainly used to treat various eye conditions, have also increased, the Bayer’in radiology business has also been strong. Similarly, birth control drugs such as SUMMER and Mirena also saw strong growth. However, the anticoagulant Xarelto’ saw a decline, mainly due to the expiration of the patent.

On the other hand, sales at the plant science branch of Bayer’in in the first quarter of the year, in part due to the slowdown in the demand for pesticides %4.1 is down. The ongoing low prices of glyphosate, the active ingredient of the Roundup weed killer, also contributed to a decline in plant science performance.

The company had previously shared that it could potentially halt glyphosate production in Louisiana’ as Chinese competition intensified.

Bayer also continues to deal with significant lawsuits related to products that the company took over during its acquisition of Monsanto’ in 2018.

Rheinmetall’in sales increase as defense demand continues to rise

by the Logistics TransportIn the the General Assembly

GermanyRheinmetall, ’'s largest arms manufacturer, is in the defense business. %With the effect of the increase of 73’, sales in the first three months of the year %It reported an increase of 46 to 2.3 billion Euro’. The company also sells %He stated that 70’in were obtained from abroad and defense revenues increased to 1.8 billion Euro’.

The results revealed that after the suspension of US military aid in the Ukraine war, the demand for defense systems and weapons in Europe’ increased. Shares of the German arms manufacturer rose 1.5 percent at market opening, bringing earnings so far this year to 170’e. Germany’'s historic debt reform, which aims to increase defense and infrastructure spending, has contributed to better performance of European defense stocks in particular.

Improved market potential

Sales growth as Rheinmetall expects the pace of business development to continue throughout the year %From 25 to %He confirmed his forecast for fiscal year 2025, predicting that it will be between 30 and 2025. As noted in the special announcement on April 28, ’, the group said it could revise its annual guideline based on improving market conditions. ​​2024’ in the Group's operating result margin, including acquisitions ,2approximately in fiscal year 2025 compared to ’ %He expects a 15.5’ recovery.

“This outlook does not yet take into account the expected improvement in market potential in markets in Europe, Germany and Ukraine ’, which are particularly relevant to Rheinmetall’i as a result of geopolitical developments in recent weeks. Therefore, Rheinmetall will make the necessary guidance adjustments as the relevant requirements of defense customers become more specific throughout the year.”

Armin Papperger, chairman of the board of Rheinmetall AG’, commented: “Rheinmetall’e is needed; Customers are buying from us today. Europe must prepare itself for a new era in which we must confront with all our might the threat to our liberal values. Rheinmetall stands behind its responsibility in this groundbreaking period.”

“We must and we will. We are experiencing never-before-seen growth in the group, and we are getting closer to our goal of becoming global champions of defense. Collaborations for the future prove it. We also have promising projects in the US, UK, Italy and Ukraine, and we have a large number of large orders that will allow sales to increase further in the coming years. We are also greatly expanding our capacities through the construction of new facilities and strategic acquisitions.”

Increased profit from

Rheinmetall’in profit %It increased by 70 percent to earn €1.92 per share. Result of activity %The revenue from defence activities almost doubled to 206 million Euro’, up 49 percent to 199 million Euro’.

In particular, the Rheinmetall Candidate, an important metric for the company's defense business line, was awarded annually in the first quarter, referring to incoming orders and framework agreements with customers. 1 increased to 11 billion Euro’. The group attributed the increase primarily to orders from ’, Germany, and “ stated that it was primarily due to ”, a special fund for the German Armed Forces.

The accumulated order amount of Rheinmetall’ reached a new record of 63 billion Euro’ at the end of the first quarter, driven by many large contracts. This includes accumulated business resulting from ongoing agreements and framework agreements, as well as potential sales to civilian customers.

Sales of vehicle systems in other segments million euros increased to ’, while arms and ammunition revenues reached a new record of 599 million euros. Rheinmetall’'s candidacy for electronic solutions more than five times higher than last year, reaching €10 billion. However, due to sales of power systems, cyclical weakness in the automotive industry and consequent delays in project execution, %It declined 6.7 to 505 million Euro’.

Novo Nordisk cuts off guidance as competition in the weight loss drug market increases

by the Logistics TransportIn the the General Assembly

Europe’'s largest pharmaceutical company reported earnings in the first quarter that exceeded analysts' expectations, but lowered its all-year forecast. Novo Nordisk at constant exchange rates (CER) of 2025 sales growth, down 3 and 5 points respectively from previous estimates %from 13 to tween 21 and operating profit growth is %From 16 to %He expects it to be between 24.

Lars Fruergaard Jørgensen, Chief Executive Officer of “ABDWe have lowered our forecast for the whole year due to the planned low-brand GLP-1 penetration, which is affected by the rapid expansion of compositions in ’. We are actively focused on efforts to prevent illegal and unsafe compounds and expand patients' access to our GLP-1 treatments, ” said.

Novo Nordisk’in shares open European market despite downgrade %It's up 4.4. However, the stock has been around since the beginning of the year, compared to the steady performance of Eli Lilly’, its main competitor in the USA’. %He's down 26 percent.

Category: Compound pressures

Demand for GLP-1 weight loss drugs increased throughout 2024, significantly outpacing supply. Under the U.S. Food and Drug Administration's (FDA) policy, compound pharmacies are allowed to produce copies of drugs that fall short of supply. This allowed smaller telehealth competitors to sell cheaper, compound versions of weight loss treatments such as Wegovy and Eli Lilly’nin Zepbound’u.

Although the FDA announced in February that deficiencies had ended, it allowed a transition period for compound versions until May 22, ’. In response to rising price pressure, Novo Nordisk cut its cost at Wegovy’'s online pharmacy NovoCare’ by more than half following a similar move by Eli Lilly’.

With nearly 1 billion people living with obesity worldwide and only a few million receiving treatment, Novo Nordisk continues to make Wegovy“ available globally, ’ said. CFO Karsten Munk Knudsen said he expects Wegovy sales to accelerate in the third quarter.

Profit exceeded expectations

Net profit per year %Net sales increased by 20 to 38.8 billion Danish kroner (EUR 5.2 billion) %increased by 18 to 78.1 billion krona (EUR 10.5 billion); They both exceeded consensus estimates. Sales of the company's core diabetes and obesity care division ’ increase and GLP-1 diabetes drug sales With the effect of the ’ increase increased to 73.5 billion krona (9.9 billion euros). All figures are on CER’.

Novo Nordisk also emphasized the completion of the REDEFINE 2 trial of the new generation obesity drug ÇağrıSema’. The treatment is %It reduced weight by 15.7 percent. Novo Nordisk expects to apply for the first regulatory approval of ÇağrıSema’ in the first quarter of next year. However, the result, which was first announced in March, was foreseen. %It disappointed investors who fell below the 25’ weight reduction. Eli Lilly last year for his latest weight-loss drug, retatrutide %He announced the results of the trial, which showed 24 weight loss.

Jørgensen said, "As part of “ R&D, we are pleased to have completed the last significant trial for our next-generation obesity treatment CagriSema and applied for U.S. approval for oral semaglutide 25 mg, which has the potential to be the first oral GLP-1 treatment for obesity."

Diageo plc warns profits will fall by millions if U.S. tariffs continue

by the Logistics TransportIn the the General Assembly

British beverage maker Diageo plc announced its mid-term sales forecast for fiscal year 2025, ending December 31, 2024’te, on Tuesday, and retracted its mid-term sales forecast due to rising U.S. tariff uncertainty.

The company said its profits could fall by nearly $200 million (€193.7 million) in the second half of 2025 if tariffs threatened by U.S. President Donald Trump ’ on Canada and Mexico ’ come into effect.

Diageo plc’'s share price Tuesday afternoon %It's down 1.3.

The company owns more than 200 ’ brands, including Guinness, Johnnie Walker, Bailey’s and Captain Morgan’, and sells in almost 180 countries.

Currently, Diageo exports whiskey from ’ to USA’ye Canada, one of its main markets, and tequila from Mexico’. The North American market is Diageo’'s largest net sales source, as well as the largest share of the alcoholic beverages market in terms of volume.

Therefore, any tariff that USA’ applies to Canada or Mexico’ may have far-reaching consequences for Diageo.

The 25 percent ’ tariffs on Canada and Mexico, which Trump’ is due to impose on Tuesday, have now been delayed by a month. This followed talks with Canadian prime minister Justin Trudeau and Mexican president Claudia Sheinbaum.

Previously, the company's medium-term organic sales growth target %From 5 to %It was between 7. This target was removed as fears of a global trade war increased, affecting recovery rates in many key markets.

Diageo also underlined that future developments make it difficult to provide updated guidance on this goal.

But he assured investors that he would share more regular trading updates and short-term guidance in the meantime.

Diageo reports weak results in fourth quarter

Reported net sales due to challenging foreign exchange market %It fell 0.6 percent to $10.9 billion (€10.6 billion). But organic net sales %It reached $101 million (97.8 million euros) with an increase of 1, but the drop in volumes limited gains somewhat.

Reported operating profit is also affected by adverse foreign exchange conditions %While 4.9 declined, organic operating profit also fell. %1.2 is down.

Earnings per share (EPS) exceptionally %It fell by 9.6 percent, mainly due to the poor performance of Moët Hennessy’.

Diageo faced a worldwide decline in demand for its premium brands after consumers turned to cheaper brands due to the ongoing cost-of-living crisis in various markets.

Debra Crew, CEO of Diageo plc’, said in a 25 Fiscal Year interim earnings press release on the company's website: “ Growth in four of our five regions was supported by market share gains. In particular, we have outperformed the market in North American ’ with high-quality share growth and positive organic net sales growth thanks to strong implementation and momentum in Don Julio and Crown Royal’.

“I'm also particularly proud of the performance of our iconic Guinness brand, backed by brand building expertise, innovation and growing global momentum, delivering double-digit growth in the eighth consecutive half. Although the pace of recovery is slower in several key markets, we maintain confidence in positive long-term industry fundamentals and, more importantly, in our ability to surpass the market.”

What do analysts think about Diageo’'s results?

Quilter Cheviot research head Chris Beckett said in an email note: “Diageo’'s results for today's semester are satisfactory and probably exceeded market expectations. We expected stability in performance and sales %1 increase and profit %With a reduction of 1, this was the stability we were looking for.

The “ market, %From 5 to %7 may react negatively to the removal of medium-term direction towards organic sales growth. This goal was set during the pandemic, when demand was extraordinarily high, and this does not make it realistic in the current environment. While we're not too worried about the removal of this guide, some are likely to take this goal badly.”

“We do not believe that there has been a significant decline in the demand for high-quality alcoholic beverage brands; Instead, there is a temporary soft period that will heal. - ”

Russ Mould, investment director at AJ Bell’in, said in an email note: “Diageo’ has very little good news so far at 2025’. First there was the threat of having to add cancer warnings to beverage labels, and now the company has withdrawn its medium-term guidance.

“ is one of the first companies to go beyond vaguely discussing the threat posed by U.S. tariffs and actively talk about the impact and how to try to mitigate it. Diageo imports a significant portion of U.S. sales from Mexico and Canada, so we'll be relieved to see that tax enforcement for these two countries is postponed for now.’

“If tariffs are eventually implemented, reflecting these extra costs to consumers will be a test of Diageo’'s pricing power. Although the group's income was slightly above the estimates, the financial results were not extraordinary. Dividends were kept steady as a sign of uncertain outlook and that sales of major liquor brands such as Tanqueray, Gordon’s and Smirnoff were under pressure.”